Current position of multikinase inhibitors monotherapy in the treatment of metastatic kidney cancer

04/2020

MUDr. Tomáš Svoboda, Ph.D.

Onkologická a radioterapeutická klinika LF UK a FN, Plzeň

SUMMARY

We have a long-term and good experience with multikinase inhibitors in the treatment of metastatic kidney cancer. However, modern immunotherapy by inhibitors of programmed cell death receptor 1 (PD-1) and programmed cell death-ligand 1 (PD-L1) shows itself to be highly effective and represents next treatment alternative moving from further therapy lines to primary treatment. Both groups of these drugs are highly different, we do not have any appropriate predictors to prefer one of them and also it's toxicity profiles seem to vary but are frequent. Moreover, we do not have enough data of higher immunotherapy effectivity in this indication so we to acknowledge position of tyrosine kinase inhibitor monotherapy remains to be strong, it can be used successfuiiy in primary treatment whiie ieaving immunotherapy for further lines, as far as it is possible to switch sequencing of these groups of drugs.

Key words

metastatic kidney cancer, radical nephrectomy, multikinase inhibitors, PD-1 and PD-L1 immunotherapy, treatment response predictors, chemotherapy